High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody
Top Cited Papers
Open Access
- 17 April 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 139 (8), 2131-2135
- https://doi.org/10.1093/brain/aww054
Abstract
Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients.This publication has 16 references indexed in Scilit:
- Clinical and genetic associations of autoantibodies to 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme a reductase in patients with immune‐mediated myositis and necrotizing myopathyMuscle & Nerve, 2014
- Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing MyopathiesMedicine, 2014
- Association of the Autoimmune Disease Scleroderma with an Immunologic Response to CancerScience, 2014
- Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodiesArthritis Research & Therapy, 2014
- Acquired necrotizing myopathiesCurrent Opinion in Neurology, 2013
- Most Patients With Cancer‐Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP‐2 or Transcription Intermediary Factor 1γArthritis & Rheumatism, 2013
- Malignancy Is Associated with Dermatomyositis But Not Polymyositis in Northern New England, USAThe Journal of Rheumatology, 2009
- 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The NetherlandsNeuromuscular Disorders, 2004
- Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based studyThe Lancet, 2001
- Paraneoplastic necrotizing myopathyNeurology, 1998